Cargando…
Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
A real-world analysis was conducted in Italy among sickle cell disease (SCD) patients to evaluate the epidemiology of SCD, describe patients’ characteristics and the therapeutic and economic burden. A retrospective analysis of administrative databases of various Italian entities was carried out. All...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821386/ https://www.ncbi.nlm.nih.gov/pubmed/36614918 http://dx.doi.org/10.3390/jcm12010117 |
_version_ | 1784865684858077184 |
---|---|
author | De Franceschi, Lucia Castiglioni, Chiara Condorelli, Claudia Valsecchi, Diletta Premoli, Eleonora Fiocchi, Carina Perrone, Valentina Esposti, Luca Degli Forni, Gian Luca |
author_facet | De Franceschi, Lucia Castiglioni, Chiara Condorelli, Claudia Valsecchi, Diletta Premoli, Eleonora Fiocchi, Carina Perrone, Valentina Esposti, Luca Degli Forni, Gian Luca |
author_sort | De Franceschi, Lucia |
collection | PubMed |
description | A real-world analysis was conducted in Italy among sickle cell disease (SCD) patients to evaluate the epidemiology of SCD, describe patients’ characteristics and the therapeutic and economic burden. A retrospective analysis of administrative databases of various Italian entities was carried out. All patients with ≥1 hospitalization with SCD diagnosis were included from 01/2010-12/2017 (up to 12/2018 for epidemiologic analysis). The index date corresponded to the first SCD diagnosis. In 2018, SCD incidence rate was 0.93/100,000, the prevalence was estimated at 13.1/100,000. Overall, 1816 patients were included. During the 1st year of follow-up, 50.7% of patients had one all-cause hospitalization, 27.8% had 2, 10.4% had 3, and 11.1% had ≥4. Over follow-up, 6.1–7.2% of patients were treated with SCD-specific, 58.4–69.4% with SCD-related, 60.7–71.3% with SCD-complications-related drugs. Mean annual number per patient of overall treatments was 14.9 ± 13.9, hospitalizations 1.1 ± 1.1, and out-patient services 5.3 ± 7.6. The total mean direct cost per patient was EUR 7918/year (EUR 2201 drugs, EUR 3320 hospitalizations, and EUR 2397 out-patient services). The results from this real-world analysis showed a high disease burden for SCD patients with multiple hospitalizations during the follow-up. High healthcare resource utilization and costs were associated with patient’ management and were most likely underestimated since indirect costs and Emergency Room admissions were not included. |
format | Online Article Text |
id | pubmed-9821386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98213862023-01-07 Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy De Franceschi, Lucia Castiglioni, Chiara Condorelli, Claudia Valsecchi, Diletta Premoli, Eleonora Fiocchi, Carina Perrone, Valentina Esposti, Luca Degli Forni, Gian Luca J Clin Med Article A real-world analysis was conducted in Italy among sickle cell disease (SCD) patients to evaluate the epidemiology of SCD, describe patients’ characteristics and the therapeutic and economic burden. A retrospective analysis of administrative databases of various Italian entities was carried out. All patients with ≥1 hospitalization with SCD diagnosis were included from 01/2010-12/2017 (up to 12/2018 for epidemiologic analysis). The index date corresponded to the first SCD diagnosis. In 2018, SCD incidence rate was 0.93/100,000, the prevalence was estimated at 13.1/100,000. Overall, 1816 patients were included. During the 1st year of follow-up, 50.7% of patients had one all-cause hospitalization, 27.8% had 2, 10.4% had 3, and 11.1% had ≥4. Over follow-up, 6.1–7.2% of patients were treated with SCD-specific, 58.4–69.4% with SCD-related, 60.7–71.3% with SCD-complications-related drugs. Mean annual number per patient of overall treatments was 14.9 ± 13.9, hospitalizations 1.1 ± 1.1, and out-patient services 5.3 ± 7.6. The total mean direct cost per patient was EUR 7918/year (EUR 2201 drugs, EUR 3320 hospitalizations, and EUR 2397 out-patient services). The results from this real-world analysis showed a high disease burden for SCD patients with multiple hospitalizations during the follow-up. High healthcare resource utilization and costs were associated with patient’ management and were most likely underestimated since indirect costs and Emergency Room admissions were not included. MDPI 2022-12-23 /pmc/articles/PMC9821386/ /pubmed/36614918 http://dx.doi.org/10.3390/jcm12010117 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article De Franceschi, Lucia Castiglioni, Chiara Condorelli, Claudia Valsecchi, Diletta Premoli, Eleonora Fiocchi, Carina Perrone, Valentina Esposti, Luca Degli Forni, Gian Luca Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy |
title | Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy |
title_full | Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy |
title_fullStr | Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy |
title_full_unstemmed | Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy |
title_short | Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy |
title_sort | real-world evidence on disease burden and economic impact of sickle cell disease in italy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821386/ https://www.ncbi.nlm.nih.gov/pubmed/36614918 http://dx.doi.org/10.3390/jcm12010117 |
work_keys_str_mv | AT defranceschilucia realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly AT castiglionichiara realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly AT condorelliclaudia realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly AT valsecchidiletta realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly AT premolieleonora realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly AT fiocchicarina realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly AT perronevalentina realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly AT espostilucadegli realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly AT fornigianluca realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly AT realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly |